Lithium, at low doses, is proposed to promote healthspan by inhibiting the enzyme GSK-3β, a key regulator in multiple aging pathways. This inhibition may enhance autophagy, reduce inflammation, and provide neuroprotective effects. Epidemiological studies correlate trace amounts of lithium in drinking water with increased longevity and better mental health outcomes in populations.
Verdict
A promising but unproven low-dose strategy for potential neuroprotection and longevity.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Low
EVIDENCE GRADE
B
MONTHLY COST
$5 - $20
Protocol
- Healthspan protocols typically involve low doses, ranging from 300 micrograms to 5 milligrams of elemental lithium daily.
- These doses are significantly lower than the therapeutic doses (e.g., 600-1200 mg) used for psychiatric conditions.
Flags
- The distinction between high-dose prescription use and low-dose supplement use is critical for safety.
- High therapeutic doses require regular blood monitoring due to a narrow therapeutic index.
- Long-term use at clinical doses is associated with risks of kidney and thyroid dysfunction.
- Interacts with diuretics, NSAIDs, and ACE inhibitors, which can dangerously increase lithium levels.